mirtazapine has been researched along with Depression, Endogenous in 249 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of the present paper was to evaluate the effectiveness of mirtazapine orally disintegrating tablets for nausea and sleep disturbance, which are common and distressing symptoms of cancer." | 9.13 | Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. ( Kim, JM; Kim, KM; Kim, KS; Kim, SW; Kim, YC; Shin, IS; Yang, SJ; Yoon, JS, 2008) |
| "Patients with ischemic stroke received either 30 mg mirtazapine or no antidepressant medication from day 1 after the stroke in an open, randomized study design." | 9.11 | Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. ( Bohrer, E; Heuser, I; Niedermaier, N; Schlattmann, P; Schulte, K, 2004) |
| "The aim of this open label trial was to evaluate mirtazapine tolerability and effectiveness in controlling symptomatology of patients with panic disorder." | 9.10 | Mirtazapine in the treatment of panic disorder: an open-label trial. ( Amore, M; Balista, C; Camardese, G; Carli, V; De Risio, S; Faia, V; Ferrari, G; Poterzio, F; Sarchiapone, M, 2003) |
| "In this open-label, 8-week study, the efficacy and safety of mirtazapine among 103 outpatients with DSM-IV major depressive disorder who had failed previous therapy with an SSRI (fluoxetine, paroxetine, or sertraline) were evaluated." | 9.09 | Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. ( Cohen, M; Dunner, DL; Fava, M; Greist, JH; Preskorn, SH; Trivedi, MH; Zajecka, J, 2001) |
| "Patients (n = 150) were randomized to a 6-week, double-blind study to evaluate the relative efficacy and safety of mirtazapine, amitriptyline, and placebo in the treatment of major depressive disorder symptoms." | 9.06 | Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. ( Gilvary, E; Glaudin, V; Panagides, J; Smith, WT, 1990) |
| "With this article, we intend to corroborate the assumed association between mirtazapine and arthralgia by presentation of eight case reports, and we describe a possible mechanism of action." | 8.82 | Mirtazapine-induced arthralgia. ( Passier, A; van Puijenbroek, E, 2005) |
| "The objective of the study was to investigate the effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder who received mirtazapine." | 7.91 | Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. ( Bryun, EA; Chumakov, EM; Grishina, EA; Ryzhikova, KA; Skryabin, VY; Smirnov, VV; Sychev, DA; Zastrozhin, MS, 2019) |
| "This multicenter, observational prospective cohort study addresses the risk associated with exposure to mirtazapine during pregnancy." | 7.81 | Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. ( Arnon, J; Buclin, T; Clementi, M; Eleftheriou, G; Kaplan, YC; Klinger, G; Malm, H; Maňáková, E; Merlob, P; Panchaud, A; Pistelli, A; Rothuizen, LE; Stephens, S; Te Winkel, B; Winterfeld, U, 2015) |
| " We have investigated the effects of mirtazapine on pentylenetetrazole (PTZ)- and maximal electroconvulsive shock (MES)-induced seizures in mice." | 7.74 | Mirtazapine does not affect pentylenetetrazole- and maximal electroconvulsive shock-induced seizures in mice. ( Kayir, H; Sezer, Z; Uzbay, TI; Yilmaz, I, 2007) |
| "Pancreatitis can be a rare but serious side-effect of Mirtazapine." | 7.74 | Mirtazapine associated with recurrent pancreatitis - a case report. ( Burke, J; Hussain, A, 2008) |
| " He developed severe pseudohallucinations under a treatment with moclobemide." | 7.73 | Pseudohallucinations associated with moclobemide: a case report. ( Degner, D; Grohmann, R; Kropp, S; Porzig, J; Rüther, E, 2005) |
| "The antagonism of 5-HT3 receptor by mirtazapine results in an antiemetic effect, suggesting that mirtazapine could be considered a successful antiemetic agent in patients suffering from severe nausea and vomiting." | 7.73 | Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. ( Pae, CU, 2006) |
| "A 44-year-old woman with a history of major depression and obsessive-compulsive disorder was prescribed mirtazapine." | 7.72 | Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report. ( Chen, JL; Karwa, M; Spinowitz, N, 2003) |
| "To report a case of serotonin syndrome (SS) resulting from the addition of tramadol to a medication regimen of venlafaxine and mirtazapine." | 7.72 | Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. ( Houlihan, DJ, 2004) |
| "No similar case has been reported in the international literature, but several observations of arthralgia with mianserin are mentioned." | 7.71 | First report of mirtazapine-induced arthralgia. ( Bourin, M; Jolliet, P; Veyrac, G, 2001) |
| "Mirtazapine was tolerated better than amitriptyline treatment." | 6.73 | Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. ( Akdeniz, F; Altintoprak, AE; Coskunol, H; Kitapcioglu, G; Zorlu, N, 2008) |
| "Major depressive disorder and alcohol dependence are common and serious mental illnesses." | 6.72 | Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study. ( Cho, SN; Choi, SB; Hwang, IB; Jeong, YC; Kim, DJ; Kim, JH; Lee, CT; Lee, E; Lee, HK; Lee, YS; Namkoong, K; Oh, DY; Pae, CU; Shin, DH; Shin, YC; Yoon, SJ, 2006) |
| "Mirtazapine treatment was also related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ at various time points." | 6.69 | Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. ( Agren, H; Behnke, K; Helsdingen, JT; Leinonen, E; Skarstein, J, 1999) |
| "Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants and trazodone, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects, in particular gastrointestinal adverse effects and sexual dysfunction." | 6.40 | A risk-benefit assessment of mirtazapine in the treatment of depression. ( Kasper, S; Praschak-Rieder, N; Tauscher, J; Wolf, R, 1997) |
| "Tacrolimus blood levels were higher than 15 ng/ml." | 5.35 | Hypotension, as consequence of the interaction between tacrolimus and mirtazapine, in a patient with renal transplant. ( Alvarez, M; Corbacho, L; Fraile, P; Garcia, T; Garcia-Cosmes, P; Tabernero, JM, 2009) |
| "Mirtazapine is a novel piperazinoazepine antidepressant, unrelated to any known class of antidepressants." | 5.33 | Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. ( De Santis, M; Diav-Citrin, O; Djulus, J; Einarson, A; Einarson, TR; Kennedy, D; Koren, G; Shakir, S; Voyer Lavigne, S; Wilton, L, 2006) |
| " Based on the case report of a patient who developed mania with higher than recommended dosage of mirtazapine, we review the literature on the atypical nature of manic symptoms with mirtazapine." | 5.31 | Dysphoric mania induced by high-dose mirtazapine: a case for 'norepinephrine syndrome'? ( Bhanji, NH; Chouinard, G; Margolese, HC; Saint-Laurent, M, 2002) |
| " Six hundred and sixty-five outpatients with nonpsychotic, major depressive disorder were prospectively randomized to treatment with either a selective serotonin reuptake inhibitor (SSRI) monotherapy (escitalopram plus placebo) or one of two antidepressant medication combinations (bupropion-sustained release plus escitalopram, or venlafaxine-extended release plus mirtazapine)." | 5.16 | Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. ( Davis, LL; Fava, M; Friedman, ES; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2012) |
| "Prior findings concerning the use of mirtazapine in the treatment of a variety of substance use disorders and its antagonistic actions at the serotonin 5-HT(2A) receptor suggest that this drug may have efficacy in the treatment of cocaine dependence in the presence of a depressive disorder." | 5.16 | The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. ( Afshar, M; Ciraulo, DA; Colaneri, LS; Devine, E; Knapp, CM; Putnam, MA; Sarid-Segal, O; Tozier, L; Waters, ME, 2012) |
| "The purpose of the present paper was to evaluate the effectiveness of mirtazapine orally disintegrating tablets for nausea and sleep disturbance, which are common and distressing symptoms of cancer." | 5.13 | Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. ( Kim, JM; Kim, KM; Kim, KS; Kim, SW; Kim, YC; Shin, IS; Yang, SJ; Yoon, JS, 2008) |
| " Mirtazapine, a widely used antidepressant, induces adverse metabolic effects such as an increase in body weight." | 5.12 | Effect of mirtazapine treatment on body composition and metabolism. ( Deisenhammer, EA; Ebenbichler, CF; Engl, J; Hinterhuber, H; Kramer-Reinstadler, K; Laimer, M; Lechner-Schoner, T; Patsch, JR; Rauchenzauner, M; Strauss, R, 2006) |
| "Patients with ischemic stroke received either 30 mg mirtazapine or no antidepressant medication from day 1 after the stroke in an open, randomized study design." | 5.11 | Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. ( Bohrer, E; Heuser, I; Niedermaier, N; Schlattmann, P; Schulte, K, 2004) |
| "The aim of this open label trial was to evaluate mirtazapine tolerability and effectiveness in controlling symptomatology of patients with panic disorder." | 5.10 | Mirtazapine in the treatment of panic disorder: an open-label trial. ( Amore, M; Balista, C; Camardese, G; Carli, V; De Risio, S; Faia, V; Ferrari, G; Poterzio, F; Sarchiapone, M, 2003) |
| "Primary care patients with a major depressive disorder and 17-item Hamilton Rating Scale for Depression (17-HAM-D) score >18 were randomized to 24 weeks of treatment with mirtazapine 30-45 mg/day (n=99) or paroxetine 20-30 mg/day (n=98)." | 5.10 | A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. ( Angus, M; Crawford, GM; Hamilton, L; Wade, A; Wilson, R, 2003) |
| "Mirtazapine was administered to 10 patients with DSM-IV major depressive disorder and comorbid GAD in an 8-week open-label study." | 5.09 | Mirtazapine in major depression with comorbid generalized anxiety disorder. ( DeVane, CL; Freund, BV; Goodnick, PJ; Puig, A, 1999) |
| "Nineteen patients (12 women and 7 men), with SSRI-induced sexual dysfunction who were in remission from major depressive disorder (total Hamilton Rating Scale for Depression [HAM-D] score < or = 10), were switched to open-label mirtazapine for up to 6 weeks." | 5.09 | Mirtazapine substitution in SSRI-induced sexual dysfunction. ( Delgado, P; Gelenberg, AJ; Laukes, C; McGahuey, C; Moreno, F; Okayli, G; Zentner, L, 2000) |
| "In this open-label, 8-week study, the efficacy and safety of mirtazapine among 103 outpatients with DSM-IV major depressive disorder who had failed previous therapy with an SSRI (fluoxetine, paroxetine, or sertraline) were evaluated." | 5.09 | Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. ( Cohen, M; Dunner, DL; Fava, M; Greist, JH; Preskorn, SH; Trivedi, MH; Zajecka, J, 2001) |
| "The aim of this study was to conduct a naturalistic, open-label examination of the efficacy and tolerability of mirtazapine (a medication with both serotonergic and noradrenergic properties) in the treatment of associated symptoms of autism and other pervasive developmental disorders (PDDs)." | 5.09 | A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. ( Guenin, KD; Kohn, AE; McDougle, CJ; Posey, DJ; Swiezy, NB, 2001) |
| "Patients (n = 150) were randomized to a 6-week, double-blind study to evaluate the relative efficacy and safety of mirtazapine, amitriptyline, and placebo in the treatment of major depressive disorder symptoms." | 5.06 | Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. ( Gilvary, E; Glaudin, V; Panagides, J; Smith, WT, 1990) |
| "With this article, we intend to corroborate the assumed association between mirtazapine and arthralgia by presentation of eight case reports, and we describe a possible mechanism of action." | 4.82 | Mirtazapine-induced arthralgia. ( Passier, A; van Puijenbroek, E, 2005) |
| "The objective of the study was to investigate the effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder who received mirtazapine." | 3.91 | Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. ( Bryun, EA; Chumakov, EM; Grishina, EA; Ryzhikova, KA; Skryabin, VY; Smirnov, VV; Sychev, DA; Zastrozhin, MS, 2019) |
| "This multicenter, observational prospective cohort study addresses the risk associated with exposure to mirtazapine during pregnancy." | 3.81 | Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. ( Arnon, J; Buclin, T; Clementi, M; Eleftheriou, G; Kaplan, YC; Klinger, G; Malm, H; Maňáková, E; Merlob, P; Panchaud, A; Pistelli, A; Rothuizen, LE; Stephens, S; Te Winkel, B; Winterfeld, U, 2015) |
| "A 64-year-old man, diagnosed with recurrent depression, developed a neuroleptic malignant syndrome (nms) during treatment with olanzapine and mirtazapine." | 3.80 | [Electroconvulsion therapy for neuroleptic malignant syndrome]. ( Buggenhout, S; Sienaert, P; Vandenberghe, J, 2014) |
| " Notably, noradrenergic and specific serotonergic antidepressant (mirtazapine) use was significantly associated with higher prevalence of heart failure (OR 3." | 3.79 | Association of antidepressant and atypical antipsychotic use with cardiovascular events and mortality in a veteran population. ( Acharya, S; Acharya, T; Huang, J; Tringali, S, 2013) |
| " We have investigated the effects of mirtazapine on pentylenetetrazole (PTZ)- and maximal electroconvulsive shock (MES)-induced seizures in mice." | 3.74 | Mirtazapine does not affect pentylenetetrazole- and maximal electroconvulsive shock-induced seizures in mice. ( Kayir, H; Sezer, Z; Uzbay, TI; Yilmaz, I, 2007) |
| "Pancreatitis can be a rare but serious side-effect of Mirtazapine." | 3.74 | Mirtazapine associated with recurrent pancreatitis - a case report. ( Burke, J; Hussain, A, 2008) |
| " He developed severe pseudohallucinations under a treatment with moclobemide." | 3.73 | Pseudohallucinations associated with moclobemide: a case report. ( Degner, D; Grohmann, R; Kropp, S; Porzig, J; Rüther, E, 2005) |
| "The antagonism of 5-HT3 receptor by mirtazapine results in an antiemetic effect, suggesting that mirtazapine could be considered a successful antiemetic agent in patients suffering from severe nausea and vomiting." | 3.73 | Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. ( Pae, CU, 2006) |
| "A 44-year-old woman with a history of major depression and obsessive-compulsive disorder was prescribed mirtazapine." | 3.72 | Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report. ( Chen, JL; Karwa, M; Spinowitz, N, 2003) |
| "To report a case of serotonin syndrome (SS) resulting from the addition of tramadol to a medication regimen of venlafaxine and mirtazapine." | 3.72 | Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. ( Houlihan, DJ, 2004) |
| "No similar case has been reported in the international literature, but several observations of arthralgia with mianserin are mentioned." | 3.71 | First report of mirtazapine-induced arthralgia. ( Bourin, M; Jolliet, P; Veyrac, G, 2001) |
| "We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia." | 3.70 | Non-fatal mirtazapine overdose. ( Maier, S; Maris, F; Retz, W; Rösler, M, 1998) |
| "Mirtazapine was started at 15 mg at bedtime, and adjusted to 15-45 mg/day." | 2.73 | Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets? ( Betzel, JV; Holden, K; Hollander, SB; Nelson, JC; Roose, S; Salzman, C, 2007) |
| "Depression is quite common among cancer patients." | 2.73 | An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients. ( Elbi, H; Ersoy, MA; Noyan, AM, 2008) |
| "Mirtazapine was tolerated better than amitriptyline treatment." | 2.73 | Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. ( Akdeniz, F; Altintoprak, AE; Coskunol, H; Kitapcioglu, G; Zorlu, N, 2008) |
| "Major depressive disorder and alcohol dependence are common and serious mental illnesses." | 2.72 | Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study. ( Cho, SN; Choi, SB; Hwang, IB; Jeong, YC; Kim, DJ; Kim, JH; Lee, CT; Lee, E; Lee, HK; Lee, YS; Namkoong, K; Oh, DY; Pae, CU; Shin, DH; Shin, YC; Yoon, SJ, 2006) |
| "Mirtazapine was then initiated for residual depressive symptoms." | 2.71 | Migraine headache prophylaxis and treatment with low-dose mirtazapine. ( Lévy, E; Margolese, HC, 2003) |
| "Mirtazapine was administered in the newly developed fast dissolving, orally disintegrating tablet formulation." | 2.71 | Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. ( Agren, H; Bäuml, J; Behnke, K; Martin, S; Ravindran, AV; Søgaard, J; Vester-Blokland, ED, 2003) |
| "Mirtazapine treatment resulted in a statistically significantly greater improvement in quality of life than paroxetine at endpoint (P=0." | 2.71 | The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care. ( Knapp, M; Patel, A; Romeo, R; Thomas, C, 2004) |
| "Treatment with mirtazapine resulted in a non-significant decrease in betaTG and PF4 and platelet 5-HT levels." | 2.71 | Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. ( Crijns, H; Hamulyák, K; Honig, A; Lousberg, R; Scharpé, S; Schins, A; Van Melle, J, 2004) |
| "The mirtazapine dose is a weak predictor of mirtazapine plasma concentrations." | 2.71 | Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. ( Dragicevic, A; Frahnert, C; Grasmäder, K; Hiemke, C; Kühn, KU; Maier, W; Rao, ML; Verwohlt, PL; von Widdern, O; Zobel, A, 2005) |
| "Amitriptyline was better than placebo with fewer patients suffering a recurrence of symptoms, but there was no difference from placebo in the proportion of patients with sustained response." | 2.69 | Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. ( Montgomery, SA; Reimitz, PE; Zivkov, M, 1998) |
| "Mirtazapine is a novel antidepressant which has a mechanism that involves the enhancement of noradrenergic and serotonergic neurotransmission via blockade of alpha2-adrenergic autoreceptors and heteroreceptors without activity at the serotonin transporter." | 2.69 | Mirtazapine augmentation in the treatment of refractory depression. ( Carpenter, LL; Hall, JM; Jocic, Z; Price, LH; Rasmussen, SA, 1999) |
| "Imipramine was more effective against the clusters related to core symptoms of depression: "depression and guilt", "retardation", and "melancholia", respectively." | 2.69 | Depressed in-patients respond differently to imipramine and mirtazapine. ( Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW, 1999) |
| "Mirtazapine treatment was also related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ at various time points." | 2.69 | Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. ( Agren, H; Behnke, K; Helsdingen, JT; Leinonen, E; Skarstein, J, 1999) |
| " Adding risperidone to mirtazapine probably does not necessitate a change of the dosage of either drug, but more extensive investigations are needed." | 2.69 | Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. ( Doorschot, CH; Loonen, AJ; Oostelbos, MC; Sitsen, JM, 1999) |
| " Mirtazapine in fixed and ascending nocturnal dosing regimens was found to facilitate sleep, but it does not generally reduce daytime alertness." | 2.69 | Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. ( O'Hanlon, JF; Radhakishun, FS; Roes, KC; van den Bos, J; van der Heijden, BC, 2000) |
| "Mirtazapine was well tolerated, while the trazodone-treated patients experienced somnolence more frequently, particularly during the first 2 weeks of treatment." | 2.68 | Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. ( de Wilde, J; Dierick, M; Evrard, JL; Mendlewicz, J; van Moffaert, M; Vereecken, A; Wilmotte, J, 1995) |
| " The dose was adjusted to a predefined fixed blood level to avoid suboptimal dosing of imipramine." | 2.68 | A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. ( Bruijn, JA; Moleman, P; Mulder, PG; van de Wetering, BJ; van den Broek, WW; van der Mast, RC; van Hulst, AM, 1996) |
| "Mirtazapine is a medication unlike other agents used for depression both in its mechanism of action as well as its side effects." | 2.47 | Review of the use of mirtazapine in the treatment of depression. ( Benjamin, S; Doraiswamy, PM, 2011) |
| "Unipolar depression is also strongly influenced by nongenetic environmental factors (e." | 2.42 | [Genetics of depression. Current knowledge and perspectives]. ( Maier, W, 2004) |
| "Insomnia and daytime sleepiness are often associated with depression." | 2.42 | Daytime sleepiness and insomnia as correlates of depression. ( Fava, M, 2004) |
| "Failure to respond may be defined as a < 25% decrease on an accepted symptom rating scale such as the Montgomery-Asberg Depression Rating Scale (MADRS) or the Hamilton Rating Scale for Depression (HAM-D) in a patient who has received an adequate dosage for 4 weeks." | 2.41 | Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. ( Aguglia, E; Amore, M; Delgado, PL; Gastpar, M; Hawley, C; Hirschfeld, RM; Kasper, S; Linden, M; Massana, J; Mendlewicz, J; Möller, HJ; Montgomery, SA; Nemeroff, CB; Saiz, J; Such, P; Torta, R; Versiani, M, 2002) |
| "Mirtazapine has proved effective in the treatment of patients who were resistant or intolerant to selective serotonin reuptake inhibitors (SSRIs) and the switch to mirtazapine could be made immediately without the necessity for a taper period." | 2.41 | The use of mirtazapine in difficult-to-treat patient populations. ( Hirschfeld, RM, 2002) |
| " Weight gain is the most commonly reported side-effect of mirtazapine, although there is evidence to suggest that this is not a significant problem during long-term treatment." | 2.41 | Tolerability and safety aspects of mirtazapine. ( Nutt, DJ, 2002) |
| "Mirtazapine is a potent antagonist of central 2alpha-adrenergic autoreceptors, and heteroreceptors and is an antagonist of serotonin 5-HT2 and 5-HT3 receptors." | 2.41 | SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. ( Kent, JM, 2000) |
| "Mirtazapine is a noradrenergic and specific serotonergic antidepressant, characterized by a unique pharmacologic profile, favorable pharmacokinetics, and proven efficacy and safety." | 2.40 | Mirtazapine: clinical advantages in the treatment of depression. ( Burrows, GD; Kremer, CM, 1997) |
| " The rates for individual side effects with the serotonin selective reuptake inhibitors, nefazodone, and venlafaxine are presented and compared with the adverse event experience for mirtazapine." | 2.40 | Safety and tolerability of the new antidepressants. ( Nelson, JC, 1997) |
| " The meta-analysis of adverse events shows that mirtazapine was better tolerated than amitriptyline, particularly with respect to anticholinergic and cardiac adverse events." | 2.40 | Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. ( Hoff, W; Panagides, J; Reimitz, PE; Stahl, S; Zivkov, M, 1997) |
| "Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants and trazodone, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects, in particular gastrointestinal adverse effects and sexual dysfunction." | 2.40 | A risk-benefit assessment of mirtazapine in the treatment of depression. ( Kasper, S; Praschak-Rieder, N; Tauscher, J; Wolf, R, 1997) |
| "Mirtazapine is a new anti-depressant that blocks presynaptic alpha 2-adrenergic receptors and postsynaptic serotonin type 2 and type 3 receptors." | 2.40 | Mirtazapine, an antidepressant. ( Puzantian, T, 1998) |
| "Mirtazapine-treated patients demonstrated a statistically significant (p < or = ." | 2.40 | A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. ( Barkin, RL; Fawcett, J, 1998) |
| "Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) with a novel mode of action that differs from other antidepressants that are currently available." | 2.40 | Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. ( Nutt, DJ, 1998) |
| "Mirtazapine has minimal inhibitory effects on CYP1A2, CYP3A4, and CYP2D6 in vitro." | 2.40 | New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. ( Nemeroff, CB; Owen, JR, 1998) |
| "Mirtazapine is a newer antidepressant that exhibits both noradrenergic and serotonergic activity." | 2.40 | Mirtazapine: a newer antidepressant. ( Hartmann, PM, 1999) |
| "Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) which has predominantly been evaluated in the treatment of major depression." | 2.40 | Mirtazapine: a review of its use in major depression. ( Holm, KJ; Markham, A, 1999) |
| "Mirtazapine is a presynaptic alpha-2 antagonist that has dual action by increasing noradrenergic and serotonergic neurotransmission." | 2.40 | Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. ( Barkin, RL; Fawcett, J, 1998) |
| "Mirtazapine has intrinsic receptor-blocking properties (in particular, serotonin-2 [5-HT2] receptor blockade) that can be linked to an early relief of anxiety symptoms during the treatment." | 2.40 | Care of depressed patients with anxiety symptoms. ( Nutt, DJ, 1999) |
| "Therefore, early relief of insomnia in a depressed patient, in addition to alleviating other symptoms, may increase adherence to treatment and increase daytime performance and overall functioning, while complete relief of insomnia may improve prognosis." | 2.40 | Antidepressant treatment of the depressed patient with insomnia. ( Thase, ME, 1999) |
| "Mirtazapine is an antidepressant with mode of action different from other currently available antidepressants." | 2.40 | Mirtazapine: other indications. ( Falkai, P, 1999) |
| "Mirtazapine (Org 3770) is a new antidepressant with prominent alpha 2-adrenergic auto- and heteroreceptor antagonistic properties and no effect on monoamine reuptake." | 2.39 | The pharmacologic profile of mirtazapine. ( de Boer, T, 1996) |
| "Mirtazapine is a new antidepressant with a unique mode of action: it preferentially blocks the noradrenergic alpha2-auto- and heteroreceptors held responsible for controlling noradrenaline and serotonin release." | 2.39 | The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. ( de Boer, T, 1995) |
| " Long-term administration showed that this tonic activation of postsynaptic 5-HT receptors was most likely enhanced after such a treatment, as a result of a sustained increase in 5-HT neuronal activity in the presence of and due to inactivated alpha2-adrenergic heteroreceptors." | 2.39 | Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. ( Blier, P; de Montigny, C; Haddjeri, N, 1995) |
| "Mirtazapine is a novel antidepressant with a unique mode of action, which can be best summarized as a noradrenaline and specific serotonin antidepressant." | 2.39 | Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. ( Kasper, S, 1995) |
| "Psychogenic adipsic hypernatremia is an exceedingly rare and life-threatening condition, occurring in those with severe psychiatric disorders." | 1.51 | Hypernatremic Hydrophobic Transient Adipsia Without Organic or Severe Psychiatric Disorder. ( Fogelfeld, L; Robertson, G; Rodriguez, A, 2019) |
| " This study aimed to investigate the effects of mirtazapine (MIRT) alone and combined with alpha-lipoic acid (ALA) against corticosterone (CORT) induced behavioral and oxidative alterations." | 1.46 | Brain antioxidant effect of mirtazapine and reversal of sedation by its combination with alpha-lipoic acid in a model of depression induced by corticosterone. ( de Oliveira, AA; de Sousa, CNS; de Sousa, LC; Honório Júnior, JER; Macedo, D; Maes, M; Medeiros, IDS; Oliveira, TQ; Patrocínio, CFV; Vasconcelos, GS; Vasconcelos, SMM, 2017) |
| " Work status had no influence on dosage after controlling for severity of illness, patient sex, and physician specialty." | 1.36 | Prescribing a sedative antidepressant for patients at work or on sick leave under conditions of routine care. ( Linden, M; Westram, A, 2010) |
| "Haloperidol was discontinued, but mirtazapine was continued, and the vivid dream activity persisted; however, reality testing when awake was intact." | 1.36 | Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment. ( Felthous, AR; Hoevet, R; Wenger, PJ, 2010) |
| "For patients with unipolar depression, discharge rates were higher when they were prescribed one of 'the four' and highest when prescribed escitalopram." | 1.36 | An audit to compare discharge rates between antidepressant monotherapies prescribed for pure unipolar depression versus depression in the presence of other indications. ( Agius, M; Gardner, J; Liu, K; Zaman, R, 2010) |
| "Sertraline was the antidepressant most likely to reduce suicidality in our sample." | 1.36 | An audit to compare discharge rates and suicidality between antidepressant monotherapies prescribed for unipolar depression. ( Agius, M; Gardner, J; Liu, K; Zaman, R, 2010) |
| "Sertraline was the antidepressant most likely to reduce suicidality in our sample." | 1.36 | Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team. ( Agius, M; Gardner, J; Liu, K; Zaman, R, 2010) |
| "Tacrolimus blood levels were higher than 15 ng/ml." | 1.35 | Hypotension, as consequence of the interaction between tacrolimus and mirtazapine, in a patient with renal transplant. ( Alvarez, M; Corbacho, L; Fraile, P; Garcia, T; Garcia-Cosmes, P; Tabernero, JM, 2009) |
| " Greater clinical severity and low initial dosing may increase the risk of switching antidepressants." | 1.35 | Antidepressant switching among adherent patients treated for depression. ( Hassan, M; Marcus, SC; Olfson, M, 2009) |
| " The sexual symptoms resolved gradually after a few days and reappeared upon every dosage increase." | 1.35 | A case of mirtazapine-induced spontaneous orgasms in a female patient. ( Ben-Zion, I; Shalev, H; Shiber, A, 2009) |
| " In 9% of patients, RLS was recorded as a side effect related to the administration of AD." | 1.35 | Restless legs syndrome as side effect of second generation antidepressants. ( Gallwitz, T; Kirch, MH; Messer, T; Rottach, KG; Schaner, BM; Teufel, LM; Zivotofsky, AZ, 2008) |
| "Mirtazapine has a pharmacological profile expected to result in a lack of sexual dysfunction." | 1.33 | Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study. ( Arias, F; Carrasco, JL; Díaz, M; Ferrando, L; Ibáñez, A; Montes, JM; Pelegrín, C; Saiz-Ruiz, J; Vicente, F; Viñas, R, 2005) |
| "One hundred sixty-five patients with cancer, consecutively admitted to the Oncology Division of San Camillo-Forlanini Hospital, were recruited to the study." | 1.33 | Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. ( Biondi, M; Cairoli, F; Costantini, A; Ferrarese, G; Pasquini, M; Picardi, A; Sternberg, C, 2006) |
| "Mirtazapine is a novel piperazinoazepine antidepressant, unrelated to any known class of antidepressants." | 1.33 | Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. ( De Santis, M; Diav-Citrin, O; Djulus, J; Einarson, A; Einarson, TR; Kennedy, D; Koren, G; Shakir, S; Voyer Lavigne, S; Wilton, L, 2006) |
| "Priapism is a "persistent erection not accompanied by sexual desire or stimulation, usually lasting more than six hours and typically involving only the corpora cavernosa." | 1.33 | Priapism and quetiapine: a case report. ( Dilley, JW; Harrison, G; Loeb, L; Nelson, K, 2006) |
| " Based on the case report of a patient who developed mania with higher than recommended dosage of mirtazapine, we review the literature on the atypical nature of manic symptoms with mirtazapine." | 1.31 | Dysphoric mania induced by high-dose mirtazapine: a case for 'norepinephrine syndrome'? ( Bhanji, NH; Chouinard, G; Margolese, HC; Saint-Laurent, M, 2002) |
| "Mirtazapine seems to be a safe compound in overdose." | 1.30 | Suicide attempts with mirtazapine overdose without complications. ( Holzbach, R; Jahn, H; Mähne, C; Pajonk, FG, 1998) |
| "Mirtazapine is a new antidepressant with a specific pharmacological profile which is different from all other currently available antidepressants." | 1.30 | [Mirtazapine in inpatient treatment of depressed patients]. ( Bailer, U; Kasper, S; Pezawas, L; Praschak-Rieder, N, 1998) |
| "Mirtazapine is a noradrenergic with specific selective serotoninergic antidepressant." | 1.30 | Mirtazapine in recurrent brief depression. ( Aschauer, HN; de Zwaan, M; Kasper, S; Pezawas, L; Stamenkovic, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.40) | 18.7374 |
| 1990's | 77 (30.92) | 18.2507 |
| 2000's | 123 (49.40) | 29.6817 |
| 2010's | 47 (18.88) | 24.3611 |
| 2020's | 1 (0.40) | 2.80 |
| Authors | Studies |
|---|---|
| Uvais, NA | 1 |
| Oliveira, TQ | 1 |
| de Sousa, CNS | 1 |
| Vasconcelos, GS | 1 |
| de Sousa, LC | 1 |
| de Oliveira, AA | 1 |
| Patrocínio, CFV | 1 |
| Medeiros, IDS | 1 |
| Honório Júnior, JER | 1 |
| Maes, M | 1 |
| Macedo, D | 1 |
| Vasconcelos, SMM | 1 |
| Gandotra, K | 1 |
| Chen, P | 1 |
| Jaskiw, GE | 1 |
| Konicki, PE | 1 |
| Strohl, KP | 1 |
| Xing, S | 1 |
| Kim, S | 1 |
| Schumock, GT | 1 |
| Touchette, DR | 1 |
| Calip, GS | 1 |
| Leow, AD | 1 |
| Lee, TA | 1 |
| Shinith, D | 1 |
| Mathilakath, A | 1 |
| Kim, DI | 1 |
| Patel, B | 1 |
| Park, JI | 1 |
| Sado, M | 1 |
| Wada, M | 1 |
| Ninomiya, A | 1 |
| Nohara, H | 1 |
| Kosugi, T | 1 |
| Arai, M | 1 |
| Endo, R | 1 |
| Mimura, M | 1 |
| Zastrozhin, MS | 1 |
| Skryabin, VY | 1 |
| Smirnov, VV | 1 |
| Grishina, EA | 1 |
| Ryzhikova, KA | 1 |
| Chumakov, EM | 1 |
| Bryun, EA | 1 |
| Sychev, DA | 1 |
| Chen, HM | 1 |
| Yang, YH | 1 |
| Chen, KJ | 1 |
| Lee, Y | 1 |
| McIntyre, RS | 1 |
| Lu, ML | 1 |
| Lee, YC | 1 |
| Hsieh, MC | 1 |
| Chen, VC | 1 |
| Rodriguez, A | 1 |
| Fogelfeld, L | 1 |
| Robertson, G | 1 |
| Acharya, T | 1 |
| Acharya, S | 1 |
| Tringali, S | 1 |
| Huang, J | 1 |
| Atigari, OV | 1 |
| Kelly, AM | 1 |
| Jabeen, Q | 1 |
| Healy, D | 1 |
| Buggenhout, S | 1 |
| Vandenberghe, J | 1 |
| Sienaert, P | 1 |
| Smit, M | 2 |
| Wennink, H | 1 |
| Heres, M | 1 |
| Dolman, KM | 2 |
| Honig, A | 5 |
| Winterfeld, U | 1 |
| Klinger, G | 1 |
| Panchaud, A | 1 |
| Stephens, S | 1 |
| Arnon, J | 1 |
| Malm, H | 1 |
| Te Winkel, B | 1 |
| Clementi, M | 1 |
| Pistelli, A | 1 |
| Maňáková, E | 1 |
| Eleftheriou, G | 1 |
| Merlob, P | 1 |
| Kaplan, YC | 1 |
| Buclin, T | 1 |
| Rothuizen, LE | 1 |
| Sockalingam, S | 1 |
| Sheehan, K | 1 |
| Feld, JJ | 1 |
| Shah, H | 1 |
| Deuschle, M | 2 |
| Gilles, M | 2 |
| Scharnholz, B | 2 |
| Kahl, KG | 1 |
| Hayashi, Y | 1 |
| Watanabe, T | 1 |
| Aoki, A | 1 |
| Ishiguro, S | 1 |
| Ueda, M | 1 |
| Akiyama, K | 1 |
| Kato, K | 1 |
| Inoue, Y | 1 |
| Tsuchimine, S | 1 |
| Yasui-Furukori, N | 1 |
| Shimoda, K | 1 |
| Chou, WH | 1 |
| Lin, FS | 1 |
| Lin, CP | 1 |
| Lin, WY | 1 |
| Yie, JC | 1 |
| Sun, WZ | 1 |
| Yrondi, A | 1 |
| Schmitt, L | 1 |
| Arbus, C | 1 |
| Lai, FY | 1 |
| Shankar, K | 1 |
| Ritz, S | 1 |
| Linden, M | 6 |
| Westram, A | 3 |
| Schmidt, LG | 1 |
| Haag, C | 1 |
| Christof, T | 1 |
| Rentzsch, C | 1 |
| Gulsun, M | 1 |
| Doruk, A | 1 |
| Schüle, C | 3 |
| Baghai, TC | 2 |
| Eser, D | 2 |
| Schwarz, M | 2 |
| Bondy, B | 1 |
| Rupprecht, R | 2 |
| Horstmann, S | 1 |
| Dose, T | 1 |
| Lucae, S | 1 |
| Kloiber, S | 1 |
| Menke, A | 1 |
| Hennings, J | 1 |
| Spieler, D | 1 |
| Uhr, M | 1 |
| Holsboer, F | 1 |
| Ising, M | 2 |
| Dang, A | 1 |
| Garg, G | 1 |
| Rataboli, PV | 1 |
| Schlotterbeck, PM | 1 |
| Vehren, T | 1 |
| Milenovic, S | 1 |
| Hiemke, C | 3 |
| Kircher, T | 1 |
| Leube, D | 1 |
| Chen, ZX | 1 |
| Wang, HQ | 1 |
| Jin, WD | 1 |
| Brunnauer, A | 1 |
| Laux, G | 1 |
| David, I | 1 |
| Fric, M | 1 |
| Hermisson, I | 1 |
| Möller, HJ | 2 |
| Fraile, P | 1 |
| Garcia-Cosmes, P | 1 |
| Garcia, T | 1 |
| Corbacho, L | 1 |
| Alvarez, M | 1 |
| Tabernero, JM | 1 |
| Marcus, SC | 1 |
| Hassan, M | 1 |
| Olfson, M | 1 |
| Benedict, A | 1 |
| Arellano, J | 1 |
| De Cock, E | 1 |
| Baird, J | 1 |
| Tonn, P | 1 |
| Reuter, SC | 1 |
| Dahmen, N | 2 |
| Laika, B | 1 |
| Leucht, S | 1 |
| Heres, S | 1 |
| Schneider, H | 1 |
| Steimer, W | 1 |
| Sukul, YR | 1 |
| Birkenhäger, TK | 2 |
| van den Broek, WW | 4 |
| Mulder, PG | 4 |
| Bruijn, JA | 5 |
| Rodriguez-Pecci, MS | 1 |
| Fuente-Aguado, Jde L | 1 |
| Montero-Tinnirello, J | 1 |
| Fernandez-Fernandez, FJ | 1 |
| Arnheim, K | 1 |
| Hennings, JM | 1 |
| Grautoff, S | 1 |
| Himmerich, H | 2 |
| Pollmächer, T | 3 |
| Schaaf, L | 2 |
| Lederbogen, F | 1 |
| Feuerhack, A | 1 |
| Bach, A | 1 |
| Kopf, D | 1 |
| Frankhauser, P | 1 |
| Onken, V | 1 |
| Schilling, C | 1 |
| Hamann, B | 1 |
| Felthous, AR | 1 |
| Wenger, PJ | 1 |
| Hoevet, R | 1 |
| Padala, KP | 1 |
| Padala, PR | 1 |
| Malloy, T | 1 |
| Burke, WJ | 1 |
| Agius, M | 5 |
| Gardner, J | 3 |
| Liu, K | 3 |
| Zaman, R | 5 |
| Kotsovolou, O | 1 |
| Ingelman-Sundberg, M | 1 |
| Lang, MA | 1 |
| Marselos, M | 1 |
| Overstreet, DH | 1 |
| Papadopoulou-Daifoti, Z | 1 |
| Johanson, I | 1 |
| Fotopoulos, A | 1 |
| Konstandi, M | 1 |
| Ruiz-Doblado, S | 1 |
| Rueda-Villar, T | 1 |
| Zurita-Gotor, P | 1 |
| Sanz-Cortes, S | 1 |
| Benjamin, S | 1 |
| Doraiswamy, PM | 1 |
| Brodaty, H | 1 |
| Banerjee, S | 1 |
| Hellier, J | 1 |
| Dewey, M | 1 |
| Romeo, R | 2 |
| Ballard, C | 1 |
| Baldwin, R | 1 |
| Bentham, P | 1 |
| Fox, C | 1 |
| Holmes, C | 1 |
| Katona, C | 1 |
| Knapp, M | 2 |
| Lawton, C | 1 |
| Lindesay, J | 1 |
| Livingston, G | 1 |
| McCrae, N | 1 |
| Moniz-Cook, E | 1 |
| Murray, J | 1 |
| Nurock, S | 1 |
| Orrell, M | 1 |
| O'Brien, J | 1 |
| Poppe, M | 1 |
| Thomas, A | 1 |
| Walwyn, R | 1 |
| Wilson, K | 1 |
| Burns, A | 1 |
| Davis, MP | 1 |
| Kirkova, J | 1 |
| Lagman, R | 1 |
| Walsh, D | 1 |
| Karafa, M | 1 |
| Holt, C | 2 |
| Butler, S | 2 |
| Friedman, ES | 1 |
| Davis, LL | 1 |
| Zisook, S | 1 |
| Wisniewski, SR | 1 |
| Trivedi, MH | 2 |
| Fava, M | 4 |
| Rush, AJ | 1 |
| Lee, YM | 1 |
| Lee, KU | 1 |
| Afshar, M | 1 |
| Knapp, CM | 1 |
| Sarid-Segal, O | 1 |
| Devine, E | 1 |
| Colaneri, LS | 1 |
| Tozier, L | 1 |
| Waters, ME | 1 |
| Putnam, MA | 1 |
| Ciraulo, DA | 1 |
| Boessen, R | 1 |
| Groenwold, RH | 1 |
| Knol, MJ | 1 |
| Grobbee, DE | 1 |
| Roes, KC | 3 |
| Knud Larsen, J | 1 |
| Nagata, T | 1 |
| Shinagawa, S | 1 |
| Tagai, K | 1 |
| Nakayama, K | 1 |
| van den Brink, RH | 1 |
| van Melle, JP | 2 |
| Schene, AH | 2 |
| Crijns, HJ | 1 |
| Lambert, FP | 1 |
| Ormel, J | 2 |
| Abraham, G | 2 |
| Anghelescu, I | 2 |
| Klawe, C | 2 |
| Hirschfeld, RM | 3 |
| Montgomery, SA | 4 |
| Aguglia, E | 1 |
| Amore, M | 2 |
| Delgado, PL | 2 |
| Gastpar, M | 1 |
| Hawley, C | 1 |
| Kasper, S | 7 |
| Massana, J | 1 |
| Mendlewicz, J | 2 |
| Nemeroff, CB | 2 |
| Saiz, J | 1 |
| Such, P | 1 |
| Torta, R | 1 |
| Versiani, M | 2 |
| Benkert, O | 3 |
| Muller, M | 1 |
| Szegedi, A | 3 |
| Thompson, C | 2 |
| Nutt, DJ | 3 |
| Bhanji, NH | 1 |
| Margolese, HC | 2 |
| Saint-Laurent, M | 1 |
| Chouinard, G | 1 |
| Nowakowska, E | 1 |
| Kus, K | 1 |
| Bobkiewicz-Kozłowska, T | 1 |
| Sarchiapone, M | 1 |
| De Risio, S | 1 |
| Carli, V | 1 |
| Faia, V | 1 |
| Poterzio, F | 1 |
| Balista, C | 1 |
| Camardese, G | 1 |
| Ferrari, G | 1 |
| Baghai, T | 1 |
| Bidlingmaier, M | 1 |
| Strasburger, C | 1 |
| Laakmann, G | 1 |
| Fisfalen, ME | 1 |
| Hsiung, RC | 1 |
| Wade, A | 1 |
| Crawford, GM | 1 |
| Angus, M | 1 |
| Wilson, R | 1 |
| Hamilton, L | 1 |
| Müller, MJ | 1 |
| Kohnen, R | 2 |
| Aga, VM | 1 |
| Barklage, NE | 1 |
| Jefferson, JW | 2 |
| Chen, JL | 1 |
| Spinowitz, N | 1 |
| Karwa, M | 1 |
| Lévy, E | 1 |
| Behnke, K | 2 |
| Søgaard, J | 1 |
| Martin, S | 1 |
| Bäuml, J | 1 |
| Ravindran, AV | 1 |
| Agren, H | 2 |
| Vester-Blokland, ED | 1 |
| Hong, CJ | 1 |
| Hu, WH | 1 |
| Chen, CC | 1 |
| Hsiao, CC | 1 |
| Tsai, SJ | 1 |
| Ruwe, FJ | 1 |
| Labbate, LA | 1 |
| Croft, HA | 1 |
| Oleshansky, MA | 1 |
| Roose, SP | 2 |
| Nelson, JC | 5 |
| Salzman, C | 2 |
| Hollander, SB | 3 |
| Rodrigues, H | 1 |
| Houlihan, DJ | 1 |
| Nierenberg, AA | 4 |
| Quitkin, FM | 2 |
| Kremer, C | 2 |
| Keller, MB | 2 |
| Thase, ME | 3 |
| Lynch, A | 1 |
| Madjlessi, A | 1 |
| Patel, A | 1 |
| Thomas, C | 1 |
| Rubio, G | 1 |
| San, L | 1 |
| López-Muñoz, F | 1 |
| Alamo, C | 1 |
| Maier, W | 2 |
| Hartter, S | 1 |
| Lawrence, RW | 1 |
| Prost, E | 1 |
| Pallanti, S | 1 |
| Quercioli, L | 1 |
| Bruscoli, M | 1 |
| Schins, A | 2 |
| Hamulyák, K | 1 |
| Scharpé, S | 1 |
| Lousberg, R | 1 |
| Van Melle, J | 1 |
| Crijns, H | 1 |
| Liappas, J | 1 |
| Paparrigopoulos, T | 1 |
| Tzavellas, E | 1 |
| Rabavilas, A | 1 |
| Niedermaier, N | 1 |
| Bohrer, E | 1 |
| Schulte, K | 1 |
| Schlattmann, P | 1 |
| Heuser, I | 1 |
| Moreno, R | 1 |
| Ramakers-van Moorsel, CJ | 1 |
| Schutte, AJ | 1 |
| Alevizos, B | 1 |
| Vaidakis, N | 1 |
| Alevizos, E | 1 |
| Nickel, T | 1 |
| Sonntag, A | 1 |
| Backmund, M | 1 |
| Crockford, DN | 1 |
| White, WD | 1 |
| Grasmäder, K | 1 |
| Verwohlt, PL | 1 |
| Kühn, KU | 1 |
| Frahnert, C | 1 |
| Dragicevic, A | 1 |
| von Widdern, O | 1 |
| Zobel, A | 1 |
| Rao, ML | 1 |
| Degner, D | 1 |
| Kropp, S | 1 |
| Porzig, J | 1 |
| Grohmann, R | 1 |
| Rüther, E | 1 |
| Rojo, JE | 2 |
| Gibert, K | 1 |
| Cobo, J | 1 |
| Rodriguez-Cano, E | 1 |
| Vallejo, J | 1 |
| Saiz-Ruiz, J | 1 |
| Montes, JM | 1 |
| Ibáñez, A | 1 |
| Díaz, M | 1 |
| Vicente, F | 1 |
| Pelegrín, C | 1 |
| Viñas, R | 1 |
| Arias, F | 1 |
| Carrasco, JL | 1 |
| Ferrando, L | 1 |
| Cavanagh, J | 1 |
| Patterson, J | 1 |
| Pimlott, S | 1 |
| Dewar, D | 1 |
| Eersels, J | 1 |
| Dempsey, MF | 1 |
| Wyper, D | 1 |
| Winters, NC | 1 |
| Passier, A | 1 |
| van Puijenbroek, E | 1 |
| de la Gándara, J | 1 |
| Agüera, L | 1 |
| Ros, S | 1 |
| de Pedro, JM | 1 |
| Romeo, E | 1 |
| Uzunov, DP | 1 |
| di Michele, F | 1 |
| Pasini, A | 1 |
| Kempter, H | 1 |
| Fulda, S | 1 |
| Beitinger, PA | 1 |
| Schuld, A | 1 |
| Osváth, P | 1 |
| Fekete, S | 1 |
| Vörös, V | 1 |
| Almási, J | 1 |
| Yoon, SJ | 1 |
| Pae, CU | 3 |
| Kim, DJ | 1 |
| Namkoong, K | 1 |
| Lee, E | 1 |
| Oh, DY | 1 |
| Lee, YS | 1 |
| Shin, DH | 1 |
| Jeong, YC | 1 |
| Kim, JH | 1 |
| Choi, SB | 1 |
| Hwang, IB | 1 |
| Shin, YC | 1 |
| Cho, SN | 1 |
| Lee, HK | 1 |
| Lee, CT | 1 |
| Laimer, M | 1 |
| Kramer-Reinstadler, K | 1 |
| Rauchenzauner, M | 1 |
| Lechner-Schoner, T | 1 |
| Strauss, R | 1 |
| Engl, J | 1 |
| Deisenhammer, EA | 1 |
| Hinterhuber, H | 1 |
| Patsch, JR | 1 |
| Ebenbichler, CF | 1 |
| Pasquini, M | 1 |
| Biondi, M | 1 |
| Costantini, A | 1 |
| Cairoli, F | 1 |
| Ferrarese, G | 1 |
| Picardi, A | 1 |
| Sternberg, C | 1 |
| Betzel, J | 1 |
| Smolen, P | 1 |
| Djulus, J | 1 |
| Koren, G | 1 |
| Einarson, TR | 1 |
| Wilton, L | 1 |
| Shakir, S | 1 |
| Diav-Citrin, O | 1 |
| Kennedy, D | 1 |
| Voyer Lavigne, S | 1 |
| De Santis, M | 1 |
| Einarson, A | 1 |
| Harrison, G | 1 |
| Dilley, JW | 1 |
| Loeb, L | 1 |
| Nelson, K | 1 |
| Mutschler, J | 1 |
| Czell, D | 1 |
| Kaps, M | 1 |
| Manzl, G | 1 |
| Fusar-Poli, P | 1 |
| Matteo, L | 1 |
| Luca, de M | 1 |
| Politi, P | 1 |
| Cortesi, M | 1 |
| Carboni, V | 1 |
| Baumann, P | 1 |
| Jonzier-Perey, M | 1 |
| Paus, E | 1 |
| Nikisch, G | 1 |
| Klier, CM | 1 |
| Mossaheb, N | 1 |
| Lee, A | 1 |
| Zernig, G | 1 |
| Elstner, S | 1 |
| Burian, R | 1 |
| Diefenbacher, A | 1 |
| Hannan, N | 1 |
| Hamzah, Z | 1 |
| Akinpeloye, HO | 1 |
| Meagher, D | 1 |
| Wingo, AP | 1 |
| Ghaemi, SN | 1 |
| Bajbouj, M | 1 |
| Gallinat, J | 2 |
| Lang, UE | 1 |
| Hellen, F | 1 |
| Vesper, J | 1 |
| Lisanby, SH | 1 |
| Danker-Hopfe, H | 1 |
| Neu, P | 1 |
| Holden, K | 1 |
| Roose, S | 1 |
| Betzel, JV | 1 |
| Yilmaz, I | 1 |
| Sezer, Z | 1 |
| Kayir, H | 1 |
| Uzbay, TI | 1 |
| Dubarek, W | 1 |
| Kucia, K | 1 |
| de Jonge, P | 1 |
| Kuyper, AM | 1 |
| Tulner, D | 1 |
| Hussain, A | 1 |
| Burke, J | 1 |
| Shalev, H | 1 |
| Ben-Zion, I | 1 |
| Shiber, A | 1 |
| Ersoy, MA | 1 |
| Noyan, AM | 1 |
| Elbi, H | 1 |
| Kim, SW | 1 |
| Shin, IS | 1 |
| Kim, JM | 1 |
| Kim, YC | 1 |
| Kim, KS | 2 |
| Kim, KM | 1 |
| Yang, SJ | 1 |
| Yoon, JS | 1 |
| Altintoprak, AE | 1 |
| Zorlu, N | 1 |
| Coskunol, H | 1 |
| Akdeniz, F | 1 |
| Kitapcioglu, G | 1 |
| Malhi, GS | 1 |
| Ng, F | 1 |
| Berk, M | 1 |
| Borkowska, A | 1 |
| Drozdz, W | 1 |
| Ziółkowska-Kochan, M | 1 |
| Rybakowski, J | 1 |
| Rottach, KG | 1 |
| Schaner, BM | 1 |
| Kirch, MH | 1 |
| Zivotofsky, AZ | 1 |
| Teufel, LM | 1 |
| Gallwitz, T | 1 |
| Messer, T | 1 |
| Claghorn, JL | 2 |
| Lesem, MD | 1 |
| Bremner, JD | 1 |
| van Moffaert, M | 2 |
| de Wilde, J | 1 |
| Vereecken, A | 1 |
| Dierick, M | 1 |
| Evrard, JL | 1 |
| Wilmotte, J | 1 |
| Vartiainen, H | 1 |
| Leinonen, E | 2 |
| Dinan, TG | 1 |
| de Boer, T | 2 |
| Tulen, JH | 1 |
| de Man, KJ | 1 |
| Pepplinkhuizen, L | 1 |
| van den Meiracker, AH | 1 |
| Man in 't Veld, AJ | 1 |
| Høyberg, OJ | 1 |
| Maragakis, B | 1 |
| Mullin, J | 1 |
| Norum, D | 1 |
| Stordall, E | 1 |
| Ekdahl, P | 1 |
| Ose, E | 1 |
| Moksnes, KM | 1 |
| Sennef, C | 1 |
| Hoes, MJ | 2 |
| Zeijpveld, JH | 2 |
| Moleman, P | 4 |
| van Hulst, AM | 1 |
| van der Mast, RC | 1 |
| van de Wetering, BJ | 1 |
| Haddjeri, N | 1 |
| Blier, P | 3 |
| de Montigny, C | 1 |
| Marttila, M | 1 |
| Jääskeläinen, J | 1 |
| Järvi, R | 1 |
| Romanov, M | 1 |
| Miettinen, E | 1 |
| Sorri, P | 1 |
| Ahlfors, U | 1 |
| Zivkov, M | 5 |
| Pinder, RM | 2 |
| Leonard, BE | 1 |
| Delbressine, LP | 1 |
| Vos, RM | 1 |
| Burrows, GD | 1 |
| Kremer, CM | 2 |
| Pols, AG | 1 |
| Egberts, AC | 1 |
| Lenderink, AW | 1 |
| de Koning, FH | 1 |
| Leufkens, HG | 1 |
| Pedersen, L | 1 |
| Klysner, R | 1 |
| Preskorn, SH | 2 |
| Frazer, A | 1 |
| Fawcett, J | 3 |
| Barkin, RL | 3 |
| Sambunaris, A | 1 |
| Hesselink, JK | 1 |
| Pinder, R | 1 |
| Panagides, J | 3 |
| Stahl, SM | 2 |
| Gerritsen, AW | 1 |
| Farah, A | 1 |
| Stahl, S | 1 |
| Reimitz, PE | 2 |
| Hoff, W | 1 |
| Praschak-Rieder, N | 2 |
| Tauscher, J | 1 |
| Wolf, R | 1 |
| Puzantian, T | 1 |
| Normann, C | 1 |
| Hesslinger, B | 1 |
| Frauenknecht, S | 1 |
| Berger, M | 1 |
| Walden, J | 1 |
| Owen, JR | 1 |
| Benazzi, F | 1 |
| Wheatley, DP | 1 |
| Timmerman, L | 2 |
| Berigan, TR | 1 |
| Harazin, JS | 1 |
| Soutullo, CA | 1 |
| McElroy, SL | 1 |
| Keck, PE | 1 |
| Gray, R | 1 |
| Zedkova, L | 1 |
| Coupland, NJ | 1 |
| Holzbach, R | 1 |
| Jahn, H | 1 |
| Pajonk, FG | 1 |
| Mähne, C | 1 |
| Bailer, U | 1 |
| Pezawas, L | 2 |
| Retz, W | 1 |
| Maier, S | 1 |
| Maris, F | 1 |
| Rösler, M | 1 |
| Hartmann, PM | 1 |
| Stamenkovic, M | 1 |
| de Zwaan, M | 1 |
| Aschauer, HN | 1 |
| Carpenter, LL | 1 |
| Jocic, Z | 1 |
| Hall, JM | 1 |
| Rasmussen, SA | 1 |
| Price, LH | 1 |
| Holm, KJ | 1 |
| Markham, A | 1 |
| Gorman, JM | 3 |
| Westenberg, HG | 1 |
| Falkai, P | 1 |
| Goodnick, PJ | 1 |
| Puig, A | 1 |
| DeVane, CL | 1 |
| Freund, BV | 1 |
| Koutouvidis, N | 1 |
| Pratikakis, M | 1 |
| Fotiadou, A | 1 |
| Skarstein, J | 1 |
| Helsdingen, JT | 1 |
| Brown, MC | 1 |
| Nimmerrichter, AA | 1 |
| Guest, JF | 1 |
| Wright, EC | 1 |
| Loonen, AJ | 1 |
| Doorschot, CH | 1 |
| Oostelbos, MC | 1 |
| Sitsen, JM | 1 |
| Sullivan, G | 1 |
| Kent, JM | 1 |
| Gelenberg, AJ | 2 |
| McGahuey, C | 1 |
| Laukes, C | 1 |
| Okayli, G | 1 |
| Moreno, F | 1 |
| Zentner, L | 1 |
| Delgado, P | 1 |
| Blass, DM | 1 |
| Pearson, VE | 1 |
| Radhakishun, FS | 1 |
| van den Bos, J | 1 |
| van der Heijden, BC | 1 |
| O'Hanlon, JF | 1 |
| Boetsch, T | 1 |
| Padberg, F | 1 |
| Hampel, H | 1 |
| Herrmann, WM | 1 |
| Hegerl, U | 1 |
| Mofsen, R | 1 |
| Taylor, BP | 1 |
| Ihde-Scholl, T | 1 |
| Dunner, DL | 1 |
| Greist, JH | 1 |
| Zajecka, J | 1 |
| Cohen, M | 1 |
| Guelfi, JD | 1 |
| Ansseau, M | 1 |
| Kørsgaard, S | 1 |
| Hutchison, LC | 1 |
| Posey, DJ | 1 |
| Guenin, KD | 1 |
| Kohn, AE | 1 |
| Swiezy, NB | 1 |
| McDougle, CJ | 1 |
| Anttila, AK | 1 |
| Rasanen, L | 1 |
| Leinonen, EV | 1 |
| Anderson, IM | 1 |
| Jolliet, P | 1 |
| Veyrac, G | 1 |
| Bourin, M | 1 |
| Bahk, WM | 1 |
| Chae, JH | 1 |
| Jun, TY | 1 |
| Lu, R | 1 |
| Hurley, AD | 1 |
| Gourley, M | 1 |
| Kunwar, A | 1 |
| Virk, S | 1 |
| Masand, PS | 1 |
| Moreno, FA | 1 |
| Onate, L | 1 |
| Smith, WT | 1 |
| Glaudin, V | 1 |
| Gilvary, E | 1 |
| Johnstone, EE | 1 |
| Studebaker, SL | 1 |
| Ajeman, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents.[NCT03894696] | 200 participants (Anticipated) | Observational | 2019-08-01 | Not yet recruiting | |||
| Phase II Clinical Studies on Anti-addictive Therapeutic Effects of Mirtazapine in Human Subjects Addicted to Cocaine.[NCT01949571] | Phase 2 | 64 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2[NCT00519012] | Phase 4 | 200 participants (Anticipated) | Interventional | 2007-08-31 | Recruiting | ||
| Music to Improve Sleep Quality in Adults With Depression and Insomnia: a Randomized Controlled Trial Using Mixed Methods[NCT03676491] | 112 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304] | Phase 4 | 420 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544] | Phase 2 | 236 participants (Anticipated) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Cortical rTMS as a Treatment for Depression[NCT05487911] | 50 participants (Anticipated) | Interventional | 2023-06-14 | Enrolling by invitation | |||
| Functional Connectivity Alterations in Suicidal Patients Among Opioid Users[NCT05489042] | 80 participants (Anticipated) | Interventional | 2022-01-04 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
63 reviews available for mirtazapine and Depression, Endogenous
| Article | Year |
|---|---|
Mirtazapine in pregnancy and lactation - A systematic review.
Topics: Antidepressive Agents, Tricyclic; Breast Feeding; Depressive Disorder; Female; Humans; Lactation; Mi | 2016 |
[Selective serotonin reuptake inhibitor is more likely to induce sexual dysfunction than mirtazapine in treating depression].
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Erectile Dysfunction; Humans; Male; Mianserin | 2008 |
Review of the use of mirtazapine in the treatment of depression.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Humans; Mianserin; Mirtazapine; Quality of Li | 2011 |
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Do | 2011 |
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.
Topics: Antidepressive Agents; Congresses as Topic; Cyclopropanes; Decision Trees; Depressive Disorder; Drug | 2002 |
An overview of the clinical efficacy of mirtazapine.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Tria | 2002 |
Onset of action of antidepressants: results of different analyses.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; | 2002 |
The use of mirtazapine in difficult-to-treat patient populations.
Topics: Adrenergic alpha-Antagonists; Age Factors; Antidepressive Agents; Depressive Disorder; Humans; Mians | 2002 |
Tolerability and safety aspects of mirtazapine.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents; Body Weight; Depressive Disorder; Humans; Mians | 2002 |
[Pharmacological justification for the use of new antidepressant drugs].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv | 2002 |
Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation.
Topics: Antidepressive Agents; Bupropion; Controlled Clinical Trials as Topic; Depressive Disorder; Doxepin; | 2003 |
[Genetics of depression. Current knowledge and perspectives].
Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depressive | 2004 |
Daytime sleepiness and insomnia as correlates of depression.
Topics: Antidepressive Agents; Benzhydryl Compounds; Bupropion; Comorbidity; Depressive Disorder; Disorders | 2004 |
Are antidepressants safe for adolescents?
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder; Humans; Mianserin; Mirtazapine; Safet | 2005 |
Mirtazapine-induced arthralgia.
Topics: Adult; Antidepressive Agents, Tricyclic; Arthralgia; Depressive Disorder; Female; Humans; Male; Mian | 2005 |
[Depression in family practice].
Topics: Age Factors; Aged; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Depressive Disord | 2007 |
[Applications and safety of modern antidepressants in patients with liver diseases].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cycloprop | 2007 |
Noradrenergic and serotonergic abnormalities in depression: stress-induced dysfunction?
Topics: Antidepressive Agents, Tricyclic; Brain; Depressive Disorder; Growth Hormone; Humans; Hydrocortisone | 1996 |
The pharmacologic profile of mirtazapine.
Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents, Tricyclic; Autoreceptors; Behavior, An | 1996 |
The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Antidepressive Agents, Tricyclic; Arousal; Autorec | 1995 |
Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antidepressive Agent | 1995 |
Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Humans; Meta-Analysis as | 1995 |
Safety of mirtazapine: a review.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose-Response Rel | 1995 |
Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive Disorder; Humans; Mianserin; | 1997 |
The clinical relevance of preclinical data: mirtazapine, a model compound.
Topics: Animals; Antidepressive Agents, Tricyclic; Area Under Curve; Biological Availability; Biotransformat | 1997 |
Mirtazapine: clinical advantages in the treatment of depression.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Clomipramine | 1997 |
Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Depress | 1997 |
Selection of an antidepressant: mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Biotransformation; Clinical Trials as Topic; Decision Making; Depr | 1997 |
Antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; C | 1997 |
Safety and tolerability of the new antidepressants.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv | 1997 |
Efficacy issues with antidepressants.
Topics: Absenteeism; Age Factors; Amitriptyline; Antidepressive Agents; Combined Modality Therapy; Controlle | 1997 |
Development of new antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressi | 1997 |
Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Second-Generation; | 1997 |
A risk-benefit assessment of mirtazapine in the treatment of depression.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depression; Depressive Disorder; Depressive Disorder, | 1997 |
Mirtazapine, an antidepressant.
Topics: Animals; Antidepressive Agents, Tricyclic; Depressive Disorder; Humans; Mianserin; Mirtazapine | 1998 |
A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Depress | 1998 |
Efficacy of mirtazapine in clinically relevant subgroups of depressed patients.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials a | 1998 |
New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cytochrom | 1998 |
Mirtazapine: a newer antidepressant.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Interactio | 1999 |
Mirtazapine: a review of its use in major depression.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Humans; Mianserin; Mirtazapine; Randomized Co | 1999 |
Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Clinical T | 1998 |
[Two new antidepressants: mirtazapine and venlafaxine].
Topics: Adrenergic alpha-Antagonists; Benzamides; Cyclohexanols; Depressive Disorder; Drug Interactions; Fem | 1999 |
New developments in the treatment of depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; C | 1999 |
Mirtazapine: clinical overview.
Topics: Adrenergic alpha-Antagonists; Aged; Antidepressive Agents, Tricyclic; Clomipramine; Controlled Clini | 1999 |
Tolerability and patient compliance.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive | 1999 |
Mirtazapine versus selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxet | 1999 |
Pharmacology of antidepressants: selectivity or multiplicity?
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents; Depressive Disorder; Humans; Mianserin; Mirtaza | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Antidepressant treatment of the depressed patient with insomnia.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Cyclohexanols; Depressive Disorder; Fluoxetine; Human | 1999 |
Care of the sexually active depressed patient.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Clinical Tria | 1999 |
Mirtazapine: other indications.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; Depressive Dis | 1999 |
The long-term treatment of depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Chronic Disease; Combined Modality Therapy; | 1999 |
Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Austria; | 1999 |
Evolution of remission as the new standard in the treatment of depression.
Topics: Antidepressive Agents; Clinical Trials as Topic; Clomipramine; Cyclohexanols; Depressive Disorder; F | 1999 |
Noradrenergic approaches to antidepressant therapy.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; D | 2000 |
New approaches to the treatment of refractory depression.
Topics: Antidepressive Agents; Buspirone; Depressive Disorder; Drug Therapy, Combination; Humans; Lithium; M | 2000 |
SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; | 2000 |
Treatment issues related to sleep and depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Humans; M | 2000 |
Evidence of early onset of antidepressant effect in randomized controlled trials.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder; Drug Administration Schedule; | 2001 |
Possible neurobiological mechanisms underlying faster onset of antidepressant action.
Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder; Humans; Mianserin; Mirtazapine; Norepinep | 2001 |
Pharmacology of rapid-onset antidepressant treatment strategies.
Topics: Antidepressive Agents, Tricyclic; Autoreceptors; Cyclohexanols; Depressive Disorder; Drug Synergism; | 2001 |
Do some antidepressants work faster than others?
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Controlled Clinic | 2001 |
Meta-analytical studies on new antidepressants.
Topics: Adult; Aged; Amoxapine; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder | 2001 |
62 trials available for mirtazapine and Depression, Endogenous
| Article | Year |
|---|---|
Impact of the WHO depression guideline on patient care by psychiatrists: a randomized controlled trial.
Topics: Adult; Affect; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Germany; Humans; | 2008 |
Suppressive effect of mirtazapine on the HPA system in acutely depressed women seems to be transient and not related to antidepressant action.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Antidepressive Agents, Tricyclic; Bipolar Disorder; | 2009 |
The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Attention; Automobile Driving; Compu | 2008 |
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Do | 2011 |
Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Citalopram; Cyclohexanols; Depressive Dis | 2012 |
The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression.
Topics: Adult; Antidepressive Agents, Tricyclic; Cocaine; Cocaine-Related Disorders; Depressive Disorder; Do | 2012 |
Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT).
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Double-Blind Method; Follow-Up Studie | 2002 |
Mirtazapine in the treatment of panic disorder: an open-label trial.
Topics: Adult; Comorbidity; Depressive Disorder; Female; Histamine H1 Antagonists; Humans; Male; Mianserin; | 2003 |
Endocrinological effects of mirtazapine in healthy volunteers.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Adult; Antidepressive Agents, Tricyclic; Blood Pr | 2002 |
A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepress | 2003 |
Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Tricyclic; Depressive Disorder; Dou | 2003 |
Migraine headache prophylaxis and treatment with low-dose mirtazapine.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Humans; Mianserin; Migraine Di | 2003 |
Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorde | 2003 |
A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Tricyclic; Depressive Disorder; Dou | 2003 |
Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Depressive Disorder | 2003 |
Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse.
Topics: Adult; Aged; Antidepressive Agents; Chronic Disease; Depressive Disorder; Female; Humans; Long-Term | 2004 |
The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cost-Benefit Analysis; Depressive Disorder; Double-B | 2004 |
Reboxetine adjunct for partial or nonresponders to antidepressant treatment.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Drug R | 2004 |
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Topics: Adult; Age of Onset; Antidepressive Agents, Tricyclic; Citalopram; Comorbidity; Depressive Disorder; | 2004 |
Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; beta-Thromboglobulin; CD40 Antigen | 2004 |
Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Central Nervous System Depressants; | 2005 |
Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke.
Topics: Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Administration Schedule; Female; F | 2004 |
Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepress | 2005 |
Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice.
Topics: Adult; Antidepressive Agents, Tricyclic; Chi-Square Distribution; Chromatography, High Pressure Liqu | 2005 |
Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity.
Topics: 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific); Adult; Aged; Antidepressive Agents, Tricyclic; De | 2006 |
Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study.
Topics: Adult; Alcoholism; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Female; Human | 2006 |
Effect of mirtazapine treatment on body composition and metabolism.
Topics: Adipose Tissue; Adult; Antidepressive Agents, Tricyclic; Blood Glucose; Body Composition; Body Fat D | 2006 |
Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older.
Topics: Administration, Oral; Aged, 80 and over; Antidepressive Agents, Tricyclic; Depressive Disorder; Fema | 2006 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Ther | 2007 |
Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Depressive Disorder | 2007 |
Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events.
Topics: Antidepressive Agents; Cardiovascular Diseases; Cause of Death; Citalopram; Comorbidity; Depressive | 2007 |
An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antidepressive Agents, Tricyclic; Depressive Disorder; | 2008 |
Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression.
Topics: Adjustment Disorders; Administration, Oral; Adult; Aged; Antidepressive Agents, Tricyclic; Depressiv | 2008 |
Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study.
Topics: Adult; Alcoholism; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blin | 2008 |
A double-blind placebo-controlled study of Org 3770 in depressed outpatients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose-Response Relati | 1995 |
A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Constipation; Depressive Disorder; Double-Blind Met | 1995 |
Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Female; Hum | 1995 |
Double-blind study of mirtazapine and placebo in hospitalized patients with major depression.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adult; Antidepressive Agents, Tricyclic; Depressive Disorde | 1994 |
Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine (Org 3770).
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Arousal; Blood Pressure; Depressive Disorder; Double- | 1996 |
A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients.
Topics: Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose- | 1996 |
A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Female; Hum | 1996 |
A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Doxep | 1995 |
Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Depress | 1997 |
Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose- | 1998 |
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Administration | 1998 |
Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Confidence Intervals; Depressive Disorder; Double-Bli | 1998 |
Mirtazapine augmentation in the treatment of refractory depression.
Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depres | 1999 |
Mirtazapine in major depression with comorbid generalized anxiety disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Comorbidity; Depressive Disorder; Drug A | 1999 |
Depressed in-patients respond differently to imipramine and mirtazapine.
Topics: Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Anxiety | 1999 |
The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin reuptake inhibitor treatment due to sexual dysfunction.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Humans; Male; Mianserin; Mirta | 1999 |
Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders | 1999 |
Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Austria; | 1999 |
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depression; Depressive Disorder | 1999 |
Mirtazapine substitution in SSRI-induced sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Depressive Disorder; Female; Humans; Irritable Mood; Male | 2000 |
Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens.
Topics: Affect; Antidepressive Agents, Tricyclic; Attention; Depressive Disorder; Dose-Response Relationship | 2000 |
Mirtazapine compared with paroxetine in major depression.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Me | 2000 |
Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; | 2001 |
Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; | 2001 |
A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
Topics: Adolescent; Adult; Aggression; Antidepressive Agents, Tricyclic; Anxiety Disorders; Appetite; Autist | 2001 |
Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents, Second-Generation; Catecholamines; | 2002 |
Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder.
Topics: Adult; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder; | 1990 |
The effectiveness of 6-azamianserin (Org 3770) in depressed outpatients.
Topics: Adult; Depressive Disorder; Female; Humans; Male; Mianserin; Mirtazapine | 1987 |
127 other studies available for mirtazapine and Depression, Endogenous
| Article | Year |
|---|---|
Psychological Impact of the COVID-19 Pandemic Among the Elderly: A Case Series From India.
Topics: Acetamides; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Betacoronavirus; Ci | 2020 |
Brain antioxidant effect of mirtazapine and reversal of sedation by its combination with alpha-lipoic acid in a model of depression induced by corticosterone.
Topics: Animals; Antidepressive Agents, Tricyclic; Antioxidants; Brain; Brain-Derived Neurotrophic Factor; C | 2017 |
Effective Treatment of Insomnia With Mirtazapine Attenuates Concomitant Suicidal Ideation.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder; Humans; Male; Middle Aged; Mirtazapine; Sle | 2018 |
Risk of Diabetes Hospitalization or Diabetes Drug Intensification in Patients With Depression and Diabetes Using Second-Generation Antipsychotics Compared to Other Depression Therapies.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antip | 2018 |
Sleep-related eating disorder with mirtazapine.
Topics: Antidepressive Agents; Depressive Disorder; Diagnosis, Differential; Feeding and Eating Disorders; F | 2018 |
Rapid improvement of functional nausea and vomiting with mirtazapine in an elderly patient.
Topics: Aged; Antidepressive Agents; Depressive Disorder; Female; Humans; Mirtazapine; Nausea; Somatoform Di | 2019 |
Does the rapid response of an antidepressant contribute to better cost-effectiveness? Comparison between mirtazapine and SSRIs for first-line treatment of depression in Japan.
Topics: Adult; Antidepressive Agents; Cost-Benefit Analysis; Depressive Disorder; Humans; Japan; Mirtazapine | 2019 |
Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder.
Topics: Adult; Alcoholism; Comorbidity; Cytochrome P-450 CYP2D6; Depressive Disorder; Female; Genotype; Huma | 2019 |
Antidepressants Reduced Risk of Mortality in Patients With Diabetes Mellitus: A Population-Based Cohort Study in Taiwan.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cohort Studies; Co | 2019 |
Hypernatremic Hydrophobic Transient Adipsia Without Organic or Severe Psychiatric Disorder.
Topics: Antidepressive Agents; Depressive Disorder; Female; Humans; Hypernatremia; Middle Aged; Mirtazapine; | 2019 |
Association of antidepressant and atypical antipsychotic use with cardiovascular events and mortality in a veteran population.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Cardiovascular Diseases; Cross-Sectional S | 2013 |
New onset alcohol dependence linked to treatment with selective serotonin reuptake inhibitors.
Topics: Alcoholism; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Substitution; Female; Humans | 2013 |
[Electroconvulsion therapy for neuroleptic malignant syndrome].
Topics: Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Electroconvulsive Therapy; Humans; Male; | 2014 |
Mirtazapine in pregnancy and lactation: data from a case series.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents, Tricyclic; Breast Feeding; Cohort Studies | 2015 |
Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents; Birth Weight; Case-Control Studies; Depre | 2015 |
Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Comorbidity; Cooperative Behavior; Delirium; De | 2015 |
Antidepressant Treatment with Venlafaxine and Mirtazapine: no Effect on Serum Concentration of Vascular Endothelial Growth Factor (VEGF).
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder; Female; Humans; Male; Mianserin; Middle Age | 2015 |
Factors Affecting Steady-state Plasma Concentrations of Enantiomeric Mirtazapine and its Desmethylated Metabolites in Japanese Psychiatric Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antidepressive Agents, Tricyclic; Cytochrome P- | 2015 |
Mirtazapine, in orodispersible form, for patients with preoperative psychological distress: A pilot study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Disorder; Female; Human | 2016 |
["Alice in wonderland syndrome", a precursor of depressive disorder with melancholic characteristics].
Topics: Aged; Alice in Wonderland Syndrome; Antidepressive Agents, Second-Generation; Antimanic Agents; Comb | 2017 |
Mirtazapine-associated peripheral oedema.
Topics: Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Edema; Female; Humans; Lower Extremity; | 2016 |
Contents of general practitioner-patient consultations in the treatment of depression.
Topics: Counseling; Depressive Disorder; Humans; Mianserin; Mirtazapine; Patient Education as Topic; Physici | 2008 |
Mirtazapine-induced akathisia.
Topics: Adrenergic alpha-Antagonists; Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Depr | 2008 |
[General practice psychotherapy for depression].
Topics: Antidepressive Agents, Tricyclic; Combined Modality Therapy; Depressive Disorder; Family Practice; H | 2008 |
Effects of mirtazapine on dehydroepiandrosterone-sulfate and cortisol plasma concentrations in depressed patients.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents, Tricyclic; Dehydroepiandrosterone Sulfate; | 2009 |
Mirtazapine induced nightmares in an adult male.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Dreams; Humans; Male; Mianserin; Mirta | 2009 |
No influence of dialysis on mirtazapine - a case report.
Topics: Adult; Antidepressive Agents, Tricyclic; Biotransformation; Depressive Disorder; Dialysis Solutions; | 2008 |
Hypotension, as consequence of the interaction between tacrolimus and mirtazapine, in a patient with renal transplant.
Topics: Aged; Antidepressive Agents, Tricyclic; Blood Pressure; Depressive Disorder; Drug Interactions; Fema | 2009 |
Antidepressant switching among adherent patients treated for depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Dep | 2009 |
Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.
Topics: Cost-Benefit Analysis; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Duloxetine H | 2010 |
High mirtazapine plasma levels in infant after breast feeding: case report and review of the literature.
Topics: Adult; Antidepressive Agents, Tricyclic; Breast Feeding; Depressive Disorder; Female; Humans; Infant | 2009 |
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
Topics: Adult; Aged; Benzodiazepines; Cytochrome P-450 CYP1A2; Depressive Disorder; Female; Genotype; Humans | 2010 |
Trait anxiety and defensive functioning in relation to antidepressant treatment outcome.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Female; Huma | 2009 |
[Mirtazapine-associated hepatotoxicity].
Topics: Antidepressive Agents; Chemical and Drug Induced Liver Injury; Cholestasis; Depressive Disorder; Dru | 2010 |
[Psycho- and pharmacotherapy of depressions. So you combine correctly].
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Behavior Therapy; Combined M | 2009 |
Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Area Under Curve; Depressive Disorder; Female; Glucos | 2010 |
Prescribing a sedative antidepressant for patients at work or on sick leave under conditions of routine care.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Employment; Female; Humans; Linear Models; Male; | 2010 |
Does night-time cortisol excretion normalize in the long-term course of depression?
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Circadian Rhythm; | 2010 |
Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Depressive Disorder, Major; Dreams; Ha | 2010 |
New onset multimodal hallucinations associated with mirtazapine: a case report.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Hallucinatio | 2010 |
An audit to compare discharge rates between antidepressant monotherapies prescribed for pure unipolar depression versus depression in the presence of other indications.
Topics: Adult; Antidepressive Agents; Citalopram; Community Mental Health Centers; Comorbidity; Cyclohexanol | 2010 |
An audit to compare discharge rates and suicidality between antidepressant monotherapies prescribed for unipolar depression.
Topics: Adult; Antidepressive Agents; Citalopram; Community Mental Health Centers; Cyclohexanols; Depressive | 2010 |
Hepatic drug metabolizing profile of Flinders Sensitive Line rat model of depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Blotting, Western; Chromatography, | 2010 |
Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team.
Topics: Antidepressive Agents; Citalopram; Community Mental Health Services; Cyclohexanols; Depressive Disor | 2010 |
Venlafaxine plus mirtazapine as first-line treatment for melancholia: preliminary results.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv | 2010 |
Antidepressant treatment in Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Double-B | 2011 |
Intolerance to mirtazapine in advanced cancer.
Topics: Aged; Antidepressive Agents; Depressive Disorder; Disorders of Excessive Somnolence; Female; Humans; | 2011 |
An audit to compare patient factors (age, sex, social background & associated physical diagnoses) in people with refractory depression in a Bedfordshire Community Mental Health Team (BCMHT) being augmented with (A) mirtazepine, (B) atypical antipsychotics
Topics: Adult; Age Distribution; Alcoholism; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Combine | 2011 |
An audit to compare the efficacy of treatment (as indicated by discharge rates and reduction in suicidality) among patients with refractory depression in a Bedfordshire Community Mental Health Team receiving augmentation therapy with either mirtazepine or
Topics: Adult; Age Distribution; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Combined Modality T | 2011 |
What do psychiatrists talk about with their depressed patients parallel to prescribing an antidepressant?
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Combined Modality Therapy; Depression; Depres | 2011 |
Time to discontinuation among the three second-generation antidepressants in a naturalistic outpatient setting of depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Female; H | 2011 |
Classifying responders and non-responders; does it help when there is evidence of differentially responding patient groups?
Topics: Amitriptyline; Antidepressive Agents; Chi-Square Distribution; Clinical Trials as Topic; Computer Si | 2012 |
[Mirtazapine versus other antidepressive agents for depression].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; D | 2012 |
A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease.
Topics: Antidepressive Agents, Tricyclic; Basal Ganglia Diseases; Depressive Disorder; Female; Hallucination | 2013 |
Massive weight gain and hostility force mirtazapine stoppage.
Topics: Adult; Affect; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Hostility; Humans; Mia | 2002 |
Venlafaxine in a patient with idiopathic leukopenia and mirtazapine-induced severe neutropenia.
Topics: Agranulocytosis; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Comorbi | 2002 |
[Rapid treatment effect. An effective antidepressant dissolves on the tongue].
Topics: Administration, Oral; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive Disorde | 2002 |
Dysphoric mania induced by high-dose mirtazapine: a case for 'norepinephrine syndrome'?
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder; Dose-Respons | 2002 |
Glucose dysregulation and mirtazapine-induced weight gain.
Topics: Adult; Antidepressive Agents, Tricyclic; Blood Glucose; Body Mass Index; Cocaine-Related Disorders; | 2003 |
Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants.
Topics: Acetamides; Aged; Anti-Infective Agents; Comorbidity; Depressive Disorder; Drug Interactions; Humans | 2003 |
Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report.
Topics: Acute Disease; Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Diabetic Ketoacidosis; | 2003 |
Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.
Topics: Analgesics, Opioid; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Humans; Male; Mianser | 2004 |
[Gynecomastia-galactorrhea during treatment with mirtazapine].
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Depressive Disorder; Diagnosis, Different | 2004 |
Genetics in pharmacokinetics?
Topics: Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Depressive Disorder; Dose-Response Relati | 2004 |
Effect of mirtazapine versus fluoxetine on "sleep quality".
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Dose-Response Relationship, Drug | 2004 |
Mirtazapine-induced shopping spree.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Disruptive, Impulse Control, and Condu | 2004 |
Increased libido with the combined use of venlafaxine and mirtazapine.
Topics: Cyclohexanols; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Libido; Mianserin; Mi | 2005 |
Depression during therapy with interferon alpha--how long should an antidepressant treatment last?
Topics: Antidepressive Agents, Tricyclic; Antiviral Agents; Depressive Disorder; Hepatitis C; Humans; Interf | 2005 |
Mirtazapine for alcohol dependence: a case report.
Topics: Alcoholism; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Humans; Male; Mianse | 2005 |
Pseudohallucinations associated with moclobemide: a case report.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Hallucinations; Humans; Male; Mianserin; Mirtazap | 2005 |
Onset of antidepressant action: a pharmacological question?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Depressive Disorder; F | 2005 |
Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Humans; Male; Mianserin; Middl | 2005 |
Serotonin transporter residual availability during long-term antidepressant therapy does not differentiate responder and nonresponder unipolar patients.
Topics: Adult; Aging; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Dis | 2006 |
Use of antidepressant combinations: which, when and why? Results of a Spanish survey.
Topics: Antidepressive Agents; Data Collection; Depressive Disorder; Drug Therapy, Combination; Drug Utiliza | 2005 |
Changes in weight and glucose tolerance during treatment with mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Blood Glucose; Body Weight; Depressive Disorder; Female; Glucose T | 2006 |
[Changes in sexual function in mirtazapine treatment. Primary data of a national, multicenter, prospective observational study in depressed patients].
Topics: Adult; Affect; Aged; Antidepressive Agents, Tricyclic; Coitus; Depressive Disorder; Erectile Dysfunc | 2005 |
Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting.
Topics: Adult; Antiemetics; Depressive Disorder; Humans; Korea; Male; Mianserin; Mirtazapine; Nausea; Vomiti | 2006 |
Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Citalopram; Depressive D | 2006 |
Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Abortion, Therapeutic; Adult; Antidepressive Age | 2006 |
Priapism and quetiapine: a case report.
Topics: Amphetamine; Amphetamine-Related Disorders; Antipsychotic Agents; Comorbidity; Depressive Disorder; | 2006 |
[Psychotic symptoms in a case of locked-in syndrome].
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Brain Stem; Cerebral Hemorrhage; Delusions; | 2006 |
Anxiety and depression after lung transplantation: Mirtazapine as a first-choice agent?
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Disorder; Drug Interactions; Humans; | 2007 |
Mirtazapine enantiomers in blood and cerebrospinal fluid.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Administration Schedule; Humans; | 2006 |
Mirtazapine and breastfeeding: maternal and infant plasma levels.
Topics: Adult; Antidepressive Agents, Tricyclic; Breast Feeding; Depressive Disorder; Female; Humans; Infant | 2007 |
Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexano | 2007 |
STAR*D level IV methodology.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv | 2007 |
Mirtazapine does not affect pentylenetetrazole- and maximal electroconvulsive shock-induced seizures in mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Chi-Square Distribution; Depressive | 2007 |
Mirtazapine associated with recurrent pancreatitis - a case report.
Topics: Abdominal Pain; Adult; Amylases; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Dis | 2008 |
A case of mirtazapine-induced spontaneous orgasms in a female patient.
Topics: Antidepressive Agents, Tricyclic; Anxiety; Depressive Disorder; Female; Hospitals, Psychiatric; Huma | 2009 |
Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cohort Stud | 2008 |
Enhancing effect of mirtazapine on cognitive functions associated with prefrontal cortex in patients with recurrent depression.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents, Tricyclic; Case-Control Studies; Cognition | 2007 |
Restless legs syndrome as side effect of second generation antidepressants.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Depressive Disorder, M | 2008 |
Mirtazapine as treatment for serotonin syndrome.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Chronic Disease; Depressive Disorder; Female; Humans; | 1996 |
First report of mirtazapine overdose.
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Coma; Depressive Dis | 1996 |
Controversies in the diagnosis and treatment of severe depression.
Topics: Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive Disorder; Humans; Mianserin; | 1996 |
Imipramine and mirtazapine are less effective than expected.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Humans; Imipramine; Mianserin; Mirtazapine | 1997 |
Neurotransmitters in depression: noradrenaline and serotonin and their interactions.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Humans; Mianserin; Mirtazapine | 1997 |
Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Drug Resistance; | 1997 |
Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapine.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Female; | 1997 |
Safety in overdose of mirtazapine: a case report.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Confusion; Depressive Disorder; Dothiepin; Drug Ov | 1997 |
Mirtazapine and ECT combination therapy.
Topics: Aged; Antidepressive Agents, Tricyclic; Combined Modality Therapy; Depressive Disorder; Electroconvu | 1997 |
The pharmacologic rationale for the clinical use of antidepressants.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; | 1997 |
Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine.
Topics: Adult; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Depressive Disorder; Drug Interaction | 1997 |
Synergistic benefits of serotonin and noradrenaline reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Di | 1998 |
Mirtazapine withdrawal symptoms.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Therapy, Combination; Humans; Mal | 1998 |
Sexual dysfunction associated with mirtazapine: a case report.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Humans; Male; Mianserin; Mirta | 1998 |
Hypomania associated with mirtazapine augmentation of sertraline.
Topics: 1-Naphthylamine; Ambulatory Care; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Drug | 1998 |
Mirtazapene: a noradrenergic and specific serotonergic antidepressant.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Humans; Mianserin; Mirtazapine | 1998 |
Hypertension during coprescription of mirtazapine and low-dose amitriptyline.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Therapy, Combination; Hum | 1998 |
Suicide attempts with mirtazapine overdose without complications.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Overdose; Female; Humans; Mianser | 1998 |
[Mirtazapine in inpatient treatment of depressed patients].
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Bipolar Disorder; Contraindication | 1998 |
Non-fatal mirtazapine overdose.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Overdose; Female; Humans; Hypothe | 1998 |
Mirtazapine in recurrent brief depression.
Topics: Administration, Oral; Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Humans; | 1998 |
[Mirtazapine--the new standard].
Topics: Antidepressive Agents, Tricyclic; Depression; Depressive Disorder; Humans; Mianserin; Mirtazapine | 1999 |
SIADH with multiple antidepressants in a geriatric patient.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Bupropion; Cyclohexanols; Depressive Disorder; Hu | 2000 |
The role of mirtazapine in the pharmacotherapy of depression.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Depressive Disorder; Humans; Mianserin; Mirt | 2000 |
Is the EEG helpful in diagnosing and monitoring lithium intoxication? A case report and review of the literature.
Topics: Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Electroencephalography; Humans; Lithium | 2000 |
Treatment of depression in the elderly.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Geriatrics; | 2001 |
Does mirtazapine have a more rapid onset than SSRIs?
Topics: Antidepressive Agents, Tricyclic; Citalopram; Cross-Sectional Studies; Data Interpretation, Statisti | 2001 |
Mitrazapine-associated palinopsia.
Topics: Adult; Afterimage; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Humans; Illusions; | 2001 |
[Depressive disorders. A third have a chronic course].
Topics: Antidepressive Agents, Tricyclic; Chronic Disease; Clinical Trials as Topic; Depressive Disorder; Dr | 2001 |
Mirtazapine and bone marrow suppression: a case report.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Bone Marrow Diseases; Depressive Disorder | 2001 |
Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depre | 2001 |
First report of mirtazapine-induced arthralgia.
Topics: Adult; Antidepressive Agents, Tricyclic; Arthralgia; Depressive Disorder; Dose-Response Relationship | 2001 |
Mirtazapine may have the propensity for developing a restless legs syndrome? A case report.
Topics: Depressive Disorder; Electroencephalography; Female; Histamine H1 Antagonists; Humans; Mianserin; Mi | 2002 |
Dystonia induced by mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Dystonia; Humans; Male; Mianserin; Middle Age | 2002 |
Urinary incontinence with mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Humans; Male; Mianserin; Middle Aged; Mirtaza | 2002 |